What is the 13F Pro Quality Score for CERS?

13F Pro ranks CERUS CORP (CERS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CERS's current score at https://13fpro.ai/research/CERS (free sign-up required for the full ranking).

Where does 13F Pro source CERS data?

All CERUS CORP fundamentals and ownership data come directly from SEC EDGAR. CERUS CORP files with the SEC under CIK 1020214. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CERS in?

CERUS CORP (CERS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CERS research updated on 13F Pro?

CERS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

CERUS CORP(CERS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1020214 CERS stock profile & AI dashboard →

13F Pro Quality Score

29.3/100

Rank #2,412 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

30.0/100

Profitability

30.0/100

Balance Sheet

21.3/100

Earnings Quality

30.0/100

Free Cash Flow

30.0/100

Institutional Flow

54.8/100

Revenue Scale

30.0/100

Dilution Risk

17.1/100

CERS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for CERUS CORP (CERS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CERS at 29.3/100 on a 32-signal composite quality model, placing it at rank #2,412 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (21.3) and revenue growth (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 17.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), CERUS CORP reports quarterly revenue of $53.7M, net income of $-1.6M, an operating margin of -0.7%. Top institutional holders of CERS by reported 13-F value include BlackRock,, ARK Investment Management, Soleus Capital Management, L.P., based on the most recent SEC filings. CERS trades on the Nasdaq exchange and files with the SEC under CIK 1020214. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CERS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CERUS CORP directly from SEC EDGAR. CERUS CORP's 13F Pro composite quality score has ranged between 15 and 30 since 2021, currently 29.3 — an improving long-term trajectory across 28 quarterly and live scoring snapshots.

✦

Fun facts about CERUS CORP

Quirks, history, and lore behind CERS — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · small-cap · listed on Nasdaq · headquartered in Northern California.
2
The Numbers
Annual revenue in the range of roughly $30–40 million — this is not a blockbuster, it's a niche life-sciences play with a very specific lane.
3
The History
Founded in the 1990s, the company spent years developing technology to make donated blood safer — a slow, regulatory-heavy road to commercialization.
4
The Secret
Its core platform uses a photochemical treatment process to inactivate pathogens — bacteria, viruses, even parasites — in blood components before transfusion.
5
The Lore
Its INTERCEPT Blood System is cleared for platelets, plasma, and red blood cells in various markets, and has been adopted by blood centers across Europe and the U.S.
6
The Giveaway
Ticker CERS, built around making blood transfusions safer with its INTERCEPT technology — the company whose whole existence is basically a pathogen's worst nightmare.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$53.7M

Net Income

Q1 2026

$-1.6M

Free Cash Flow

Q1 2026

$-3.3M

Operating Margin

Q1 2026

-0.7%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+16.1% YoY

$233.8MFY 2025

FY22 $188.3MFY23 $186.8MFY24 $201.3MFY25 $233.8M

Net Income

+25.3% YoY

$-15.6MFY 2025

FY22 $-42.8MFY23 $-37.5MFY24 $-20.9MFY25 $-15.6M

Operating Income

+39.0% YoY

$-8.7MFY 2025

FY22 $-34.1MFY23 $-30.1MFY24 $-14.2MFY25 $-8.7M

EPS (Diluted)

+27.3% YoY

$-0.08FY 2025

FY22 $-0.24FY23 $-0.21FY24 $-0.11FY25 $-0.08

Total Assets

+10.4% YoY

$221.9MFY 2025

FY22 $218.1MFY23 $197.7MFY24 $200.9MFY25 $221.9M

Op. Cash Flow

-57.4% YoY

$4.8MFY 2025

FY22 $-25.6MFY23 $-43.2MFY24 $11.4MFY25 $4.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$233.8M +16.1%	$201.3M +7.8%	$186.8M -0.8%	$188.3M +18.1%	$159.5M +39.6%	$114.2M
Net Income	$-15.6M +25.3%	$-20.9M +44.2%	$-37.5M +12.4%	$-42.8M +21.3%	$-54.4M +9.2%	$-59.9M
Operating Income	$-8.7M +39.0%	$-14.2M +52.7%	$-30.1M +11.8%	$-34.1M +30.4%	$-48.9M +16.1%	$-58.3M
EPS (Diluted)	$-0.08 +27.3%	$-0.11 +47.6%	$-0.21 +12.5%	$-0.24 +25.0%	$-0.32 +13.5%	$-0.37
Total Assets	$221.9M +10.4%	$200.9M +1.6%	$197.7M -9.3%	$218.1M -8.2%	$237.5M +7.3%	$221.4M
Operating Cash Flow	$4.8M -57.4%	$11.4M +126.3%	$-43.2M -68.5%	$-25.6M +24.5%	$-33.9M +18.9%	$-41.8M

AI Insight: CERS Financial Trends

CERS turned operating income positive in Q3 2025 ($1M vs -$1M in Q4 2024) but remains unprofitable with inconsistent cash generation.

• Operating income improved from -$6M in Q1 2025 to -$0M in Q1 2026, reaching positive $1M in Q3 2025.

• Equity strengthened from $50M in Q2 2024 to $68M in Q1 2026, rising $18M over eight quarters.

• Operating cash flow remains volatile, swinging from $6M in Q4 2025 to -$3M in Q1 2026.

⚠ Operating cash flow turned negative in Q1 2026 after two consecutive positive quarters in Q4 2025.

⚠ Company achieved brief operating profitability in Q3 2025 but slipped back to breakeven in Q1 2026.

AI Insight: CERS Ratio Trends

Cerus Corp achieved near break-even profitability in Q3 2025 but slipped back to losses in Q1 2026.

• ROE improved dramatically from -55.6% in Q1 2025 to -0.1% in Q3 2025 before deteriorating to -9.7% in Q1 2026.

• ROIC turned positive to 8.0% in Q3 2025, the only profitable quarter in the dataset, before declining to -2.1% in Q1 2026.

• Operating margin of -0.7% and net profit margin of -3.1% in Q1 2026 indicate continued but modest losses.

⚠ Company's inability to sustain Q3 2025's near break-even performance suggests operational challenges persist.

⚠ Volatile quarterly profitability swings from -55.6% to 8.0% ROIC indicate unstable business fundamentals.

Get alerted when CERS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CERUS CORP including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CERS

BlackRock, Inc.
$39.3M21,575,419 sh
ARK Investment Management LLC
$34.9M19,161,148 sh
Soleus Capital Management, L.P.
$19.6M10,753,700 sh
BAKER BROS. ADVISORS LP
$18.2M10,008,345 sh
VANGUARD CAPITAL MANAGEMENT LLC
$14.8M8,131,778 sh
WASATCH ADVISORS LP
$9.6M5,281,136 sh
GEODE CAPITAL MANAGEMENT, LLC
$8.4M4,637,440 sh
Nikko Asset Management Americas, Inc.
$8.2M4,516,606 sh
Sumitomo Mitsui Trust Holdings, Inc.
$8.2M4,516,606 sh
SILVERCREST ASSET MANAGEMENT GROUP LLC
$7.7M4,241,411 sh

Fund	Value	Shares
BlackRock, Inc.	$39.3M	21,575,419
ARK Investment Management LLC	$34.9M	19,161,148
Soleus Capital Management, L.P.	$19.6M	10,753,700
BAKER BROS. ADVISORS LP	$18.2M	10,008,345
VANGUARD CAPITAL MANAGEMENT LLC	$14.8M	8,131,778
WASATCH ADVISORS LP	$9.6M	5,281,136
GEODE CAPITAL MANAGEMENT, LLC	$8.4M	4,637,440
Nikko Asset Management Americas, Inc.	$8.2M	4,516,606
Sumitomo Mitsui Trust Holdings, Inc.	$8.2M	4,516,606
SILVERCREST ASSET MANAGEMENT GROUP LLC	$7.7M	4,241,411

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CERS on your watchlist

Track score changes the day CERUS CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CERS a good stock to buy?

13F Pro's AI-powered analysis of CERUS CORP (CERS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CERS are available on the CERS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CERS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CERS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CERUS CORP's investment landscape.